These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2747411)
1. [The effect of fenofibrate in various types of hyperlipoproteinemias]. Sucić M Lijec Vjesn; 1989 Mar; 111(3):93-7. PubMed ID: 2747411 [TBL] [Abstract][Full Text] [Related]
2. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)]. Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341 [TBL] [Abstract][Full Text] [Related]
3. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)]. Drouin P; Méjean L; Lambert D; Wülfert E; Debry G Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342 [TBL] [Abstract][Full Text] [Related]
4. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)]. Micheli H; Pometta D; Gustafson A Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343 [TBL] [Abstract][Full Text] [Related]
5. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias. Canzler H; Bojanovski D Artery; 1980; 8(2):171-8. PubMed ID: 7458684 [TBL] [Abstract][Full Text] [Related]
6. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498 [TBL] [Abstract][Full Text] [Related]
7. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia. Lehtonen A; Viikari J Artery; 1982; 10(5):353-67. PubMed ID: 7181678 [TBL] [Abstract][Full Text] [Related]
8. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060 [TBL] [Abstract][Full Text] [Related]
9. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Farnier M; Bonnefous F; Debbas N; Irvine A Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177 [TBL] [Abstract][Full Text] [Related]
11. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Harvengt C; Heller F; Desager JP Artery; 1980; 7(1):73-82. PubMed ID: 7247733 [TBL] [Abstract][Full Text] [Related]
12. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558 [TBL] [Abstract][Full Text] [Related]
13. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic]. Ceska R; Stulc T Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407 [TBL] [Abstract][Full Text] [Related]
14. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals]. Hutt V; Klör HU; Wechsler JG; Ditschuneit H J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054 [TBL] [Abstract][Full Text] [Related]
15. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR Artery; 1985; 12(6):363-81. PubMed ID: 4051756 [TBL] [Abstract][Full Text] [Related]
16. Effect of procetofen on serum lipids and apoproteins. Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088 [TBL] [Abstract][Full Text] [Related]
17. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476 [TBL] [Abstract][Full Text] [Related]
18. [Effect of 1 month's treatment with Bezalip on the serum lipids and lipoproteins of patients with different types of hyperlipoproteinemias]. Kiriakov A; Malamov E; Apostolova Iu; Tsenov I; Tinterova Z Vutr Boles; 1983; 22(3):74-81. PubMed ID: 6649587 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias]. Reiner Z; Salzer B; Kes P Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481 [No Abstract] [Full Text] [Related]
20. The effect of etofibrate retard, bezafibrate and procetofen. Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W Artery; 1980; 8(2):128-33. PubMed ID: 7458677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]